| Literature DB >> 30210871 |
Heqian Kuang1, Fang Yang2, Yan Zhang1, Tiannan Wang1, Guoxun Chen1.
Abstract
Nutrient deficiencies and excess are involved in many aspects of human health. As a source of essential nutrients, eggs have been used worldwide to support the nutritional needs of human societies. On the other hand, eggs also contain a significant amount of cholesterol, a lipid molecule that has been associated with the development of cardiovascular diseases. Whether the increase of egg consumption will lead to elevated cholesterol absorption and disruption of cholesterol homeostasis has been a concern of debate for a while. Cholesterol homeostasis is regulated through its dietary intake, endogenous biosynthesis, utilization, and excretion. Recently, some research interests have been paid to the effects of egg consumption on cholesterol homeostasis through the intestinal cholesterol absorption. Nutrient components in eggs such as phospholipids may contribute to this process. The goals of this review are to summarize the recent progress in this area and to discuss some potential benefits of egg consumption.Entities:
Year: 2018 PMID: 30210871 PMCID: PMC6126094 DOI: 10.1155/2018/6303810
Source DB: PubMed Journal: Cholesterol ISSN: 2090-1283
Nutrient values of a medium-size boiled egg, whole milk with added vitamin D, and boiled manufacturing beefa.
|
|
|
|
| ||
|
| |||||
|
|
|
|
|
|
|
|
| |||||
|
| |||||
| Energy | kcal | 78 | 155 | 61 | 126 |
| Water | g | 37.31 | 74.62 | 88.13 | 73.1 |
| Protein | g | 6.29 | 12.58 | 3.15 | 24.21 |
| Total lipid (fat) | g | 5.3 | 10.61 | 3.25 | 3.26 |
| Carbohydrate, by difference | g | 0.56 | 1.12 | 4.8 | 0 |
| Fiber, total dietary | g | 0 | 0 | 0 | 0 |
| Sugars, total | g | 0.56 | 1.12 | 5.05 | 0 |
|
| |||||
|
| |||||
| Calcium, Ca | mg | 25 | 50 | 113 | 6 |
| Iron, Fe | mg | 0.59 | 1.19 | 0.03 | 1.78 |
| Magnesium, Mg | mg | 5 | 10 | 10 | 16 |
| Phosphorus, P | mg | 86 | 172 | 84 | 129 |
| Potassium, K | mg | 63 | 126 | 132 | 183 |
| Sodium, Na | mg | 62 | 124 | 43 | 32 |
| Zinc, Zn | mg | 0.53 | 1.05 | 0.37 | 5.02 |
|
| |||||
|
| |||||
| Vitamin C, total ascorbic acid | mg | 0 | 0 | 0 | 0 |
| Thiamin | mg | 0.033 | 0.066 | 0.046 | 0.042 |
| Riboflavin | mg | 0.257 | 0.513 | 0.169 | 0.096 |
| Niacin | mg | 0.032 | 0.064 | 0.089 | 1.759 |
| Vitamin B6 | mg | 0.06 | 0.121 | 0.036 | 0.16 |
| Folate, DFE |
| 22 | 44 | 5 | 0 |
| Vitamin B12 |
| 0.56 | 1.11 | 0.45 | 1.02 |
| Vitamin A, RAE |
| 74 | 149 | 46 | 8 |
| Vitamin A, IU | IU | 260 | 520 | 162 | 27 |
| Vitamin E ( | mg | 0.52 | 1.03 | 0.07 | 0.57 |
| Vitamin D (D2 + D3) |
| 1.1 | 2.2 | 1.3 | 0.1 |
| Vitamin D | IU | 44 | 87 | 51 | 5 |
| Vitamin K (phylloquinone) |
| 0.1 | 0.3 | 0.3 | 0 |
|
| |||||
|
| |||||
| SFAsb | g | 1.633 | 3.267 | 1.865 | 1.154 |
| MUFAsb | g | 2.038 | 4.077 | 0.812 | 0.897 |
| PUFAsb | g | 0.707 | 1.414 | 0.195 | 0.246 |
| Trans fatty acids | g | 0 | 0 | 0 | 0.078 |
| Cholesterol | mg | 186 | 373 | 10 | 67 |
aNutrient values and weights are for edible portion; bSFAs: saturated fatty acids, MUFAs: monounsaturated fatty acids, and PUFAs: polyunsaturated fatty acids.
Figure 1The structure of egg yolk lipoprotein. The outer layer of egg yolk lipoprotein is mainly composed of phospholipids, with free cholesterol scattered and integral and peripheral apolipoprotein attached. The hydrophobic triacylglycerol and cholesteryl ester exist in core.
Possible factors influencing intestinal cholesterol absorptiona,b.
|
|
|
|
|
|---|---|---|---|
|
| |||
| ↑ Cholesterol | (-) | Mouse feeding studies | Duan 2004 [ |
| Fat | |||
| ↑ Stearic Acid | ↓ | Rat feeding studies | Kelley 1978 [ |
| ↑ MUFAs | ↓ | African green monkey feeding studies | Johnson 1985 [ |
| ↑ | ↓ | African green monkey feeding studies | Johnson 1985 [ |
| ↑ Fish Oil | ↓ | Rat feeding studies | Chen 1987 [ |
| ↑ Cellulose | ↓ | Hamster feeding studies | Turley 1994 [ |
| ↑ Phytosterols | ↓ | Human intervention (see table in reference) | Nguyen 1999 [ |
| ↑ Soluble Fibers | ↓ | Rat and hamster feeding studies | Feldman 1979 [ |
| ↑ Ezetimibe | ↓ | Human and hamster feeding studies | Rosenblum 1998 [ |
| ↑ Sphingomyelin | ↓ | Mouse feeding studies | Eckhardt 2002 [ |
|
| |||
| ↓ Bile acid output | ↓ | Cyp7a1(-/-) mice | Schwarz 2001 [ |
| ↓ Bile acid/salt pool size | ↓ | Cyp7a1(-/-) mice | Schwarz 2001 [ |
| ↓ Bile acid phospholipid output | ↓ | Abcb4(-/-) mice | Wang 1998 [ |
| ↑ Bile acid cholesterol output | ↑ | Various mouse strains | Wang 2001 [ |
| ↑ Cholesterol content in bile salts | ↑ | Various mouse strains | Wang 2001 [ |
| ↑ Hydrophobic bile salt | ↑ | Mouse feeding studies | Wang 2003 [ |
| ↑ Hydrophilic bile salt | ↓ | Mouse feeding studies | Wang 2003 [ |
|
| |||
| ↓ ACAT2 | ↓ | Inhibitor in mice | Buhman 2000 [ |
| ↓ HMG-CoA R | ↓ | Inhibitor in human and mice | Hajri 1995 [ |
| ↓ ABCA1d | ↓ | Abca1 (-/-) mice | McNeish 2000 [ |
| ↓ ABCG5 and ABCG8 | ↑ | Abcg5/g8(-/-)mice | Yu 2002 [ |
| ↓ NPC1L1 | ↓ | Npc1/1(-/-) mice | Altmann 2004 [ |
| ↓ SR-BId | (-) | Sr-b1 (-/-) mice | Mardones 2001[ |
| ↑ SR-BI | ↑ | Overexpression in CHO cells | Altmann 2002 [ |
| ↑ SR-BI | ↓ | Hepatic overexpression in mice | Sehayek 1998 [ |
| ↓ Caveolin1 | (-) | Cav1 (-/-) mice | Valasek 2005 [ |
| ↓ MTP | ↓ | Inhibitor in human | Samaha 2008 [ |
| ↓ APO-B48 | ↓ | ApoB48 (-/-) mice | Young 1995 [ |
| ↑ LXRs | ↓ | Agonist in human | Repa 2000 [ |
| ↑ FXR | ↓ | Agonist in human | Repa 2000 [ |
| ↑ RXR | ↓ | Agonist in mice | Repa 2000 [ |
| ↑ PPAR | ↓ | Ppar | Knight 2003 [ |
| ↑ PPAR | ↓ | Agonist in mice | Van Der Veen 2005 [ |
|
| |||
| ↑ Small intestine transit time | ↑ | Cck-1 receptor (-/-) mice | Wang 2004 [ |
| ↑ Gastric emptying time | ↑ | Various of mouse strains | Kirby 2004 [ |
| ↓ MUC1 | ↓ | Muc1 (-/-) mice | Wang 2004 [ |
| ↓ CELd | (-) | Cel (-/-) mice | Kirby 2002 [ |
| ↓ PTL | ↓ | Ptl (-/-) mice | Huggins 2003 [ |
a Table 2 is modified from Wang 2005 [90] with supplement. bAbbreviations: MUFAs, monounsaturated fatty acids; PUFAs, polyunsaturated fatty acids; CYP7a1, cholesterol 7α-hydroxylase; ABC, ATP-binding cassette (transporter); ACAT2, acyl-CoA:cholesterol acyltransferase, isoform 2; HMG-CoA R, HMG-CoA reductase; NPC1L1, Niemann-Pick C1-Like 1; SR-BI, scavenger receptor class B member I; MTP, microsomal triglyceride transfer protein; APO, apolipoprotein; LXR, liver X receptor; FXR, farnesoid X receptor; RXR, retinoid X receptor; PPAR, peroxisomal proliferator activated receptor; CCK, cholecystokinin; MUC, mucin gene; CEL, carboxyl ester lipase; PTL, pancreatic triglyceride lipase; c↑ increase, ↓ decrease, (-) no influence. dContradictory result from different research groups.
Figure 2The cellular cholesterol partition and key enzymes of cholesterol metabolism. The cholesterol (C) from low-density lipoprotein (LDL) could be uptaken by liver cell via two ways, the endocytosis and hydrolyze LDL via lysosome or digest and uptake via lipoprotein lipase on the cell membrane. Cholesterol could be esterified into cholesteryl esters (CE) for storage in liver or be used for synthesize bile acid or oxysterol via cholesterol 7 alpha-hydroxylase (CYP7A1) on endoplasmic reticulum (ER) or via sterol 27-hydroxylase (CYP27A) in mitochondria. Cholesterol could also be synthesized de novo via enzyme on ER.
Figure 3Regulation of cholesterol homeostasis via SREBP and HMG-CoA reductase. When the cholesterol (C) or oxysterol level is high, they can bind to sterol sensing domain (SSD) of the sterol regulatory element binding protein (SREBP) cleavage activating protein (SCAP) or HMG-CoA reductase. In this case, SREBP will be stabilized on ER to be inactivated, and HMG-CoA reductase will be degraded therefore cholesterol synthesis will be inhibited. The low cholesterol level causes release of Insig and allows the SCAP/SREBP to enter the COPII coated vesicle. The vesicle will move to Golgi and the SREBP will be cleaved into the activated form. The mature SREBPs enter into nucleus to bind to sterol regulatory elements (SREs) to induce the downstream genes expression.
(a) Prospective studies
|
|
|
|
|
|
| |
|---|---|---|---|---|---|---|
|
|
| |||||
| Bernstein 2011 [ | 43,150 | 84,010 | 30-75 | 26 | Incident stroke | (-) |
| Burke | 256 | 258 | 15-88 | 14 | CHD, mortality | ↑ |
| Dawber 1982 [ | 912 | 30-59 | 24 | Incident CHD and blood cholesterol level | (-) | |
| Djoussé 2008 [ | 21,327 | 0 | 40-85 | 20 | Incident MI and stroke | (-) |
| Mortality | ↑ | |||||
| Goldberg 2014 [ | 572 | 857 | 57-75 | 11 | Incident stroke | (-) |
| Carotid atherosclerosis | ↓ | |||||
| Haring 2014 [ | 12,066 | 45-64 | 22 | Incident CHD | (-) | |
| Houston 2011 [ | 864 | 1077 | 70-79 | 9 | Incident CVD | ↑ especially in diabetic people |
| Hu | 37,851 | 80,082 | 34-75 | 14 | Incident stroke and CHD | (-) while in diabetic people may have ↑ effect |
| Mann | 4,102 | 6,700 | 16-79 | 13.3 | Ischemic heart disease mortality | ↑ |
| Nakamura 2004 [ | 5,186 | 4,077 | 30-70 | 14 | Stroke and CHD mortality | ↑ in women |
| Nakamura 2006 [ | 43,319 | 47,416 | 40-69 | 10.2 | Incident CHD | (-) |
| Qureshi 2006 [ | 3,756 | 5,978 | 25-74 | 15.9 | All stroke, CAD | (-) while in diabetic people may have ↑ effect |
| Sauvaget 2003 [ | 15,350 | 24,999 | 34-103 | 16 | Stroke mortality | (-) |
| Scrafford 2011 [ | 14,946 | >17 | 8.8 | CHD and Stroke mortality | (-) | |
| Zazpe | 6,170 | 8,015 | 20-90 | 5.8 | Incident CVD | (-) |
| Voutilainen 2013 [ | 1,019 | 0 | 51.9 (Mean) | 18.8 | Carotid atherosclerosis, incident MI | (-) |
| Pang | 8,131 | 8,463 | >60 | N/A | Serum LDL and total cholesterol | ↑ |
| Spence 2012 [ | 669 | 593 | 46-77 | N/A | Carotid plaque area | ↑ |
| Trichopoulou 2006 [ | 424 | 589 | 50-80 (Adult diabetics) | 4.5 (mean) | Mortality | ↑ |
(b) Human intervention
|
|
|
|
|
|
|
| |
|---|---|---|---|---|---|---|---|
|
|
| ||||||
| Missimer 2017 [ | 24 | 26 | 18-30 | 11c | 2 eggs/day vs. oatmeal | Serum LDL and HDL | ↑ |
| Serum LDL/HDL | (-) | ||||||
| Serum ghrelin | ↑ satiety | ||||||
|
| |||||||
| Lemos 2018 [ | 16 | 14 | 18-20 | 13 | 3 eggs/day vs. choline bitartrate supplement | Serum LDL and HDL | ↑ |
| Serum LDL/HDL | (-) | ||||||
| SREBPs and HMG-CoA reductase level | ↓ cholesterol biosynthesis | ||||||
|
| |||||||
| Herron 2002 [ | 0 | 51 | 18-49 (pre-menopausal) | 11c | 1 egg/day vs. | Serum LDL and HDL | ↑ |
| Serum LDL/HDL | (-) | ||||||
| CETP level | ↑ reverse cholesterol transport | ||||||
|
| |||||||
| Herron 2003 [ | 40 | 0 | 18-57 | 11c | 1 egg/day vs. | Serum LDL and HDL | ↑ |
| Serum LDL/HDL | ↑ only in hyper-respondersd | ||||||
| CETP, LCAT level | ↑ reverse cholesterol transport | ||||||
|
| |||||||
| Mutungi 2008 [ | 28 | 0 | 40-70 (overweight/obese) | 12 | CRD: | Serum LDL/HDL | (-) |
| Serum HDL | ↑ | ||||||
|
| |||||||
| Greene 2005 [ | 13 | 29 | >60 | 11c | 3 eggs/day vs. SUB | Serum LDL and HDL | ↑ |
| Serum LDL/HDL | (-) | ||||||
|
| |||||||
| Ballesteros 2004 [ | 25 | 29 | 8-12 | 11c | 2 eggs/day vs. SUB | Serum LDL/HDL | (-) |
|
| |||||||
| Knopp 2003 [ | 78 | 119 | 43-67 | 4 | 0, 2 and 4 eggs/day | Serum LDL and HDL | ↑ |
|
| |||||||
| Knopp 1997 [ | 86 | 45 | 41-68 (HC or HL) | 12 | 2 eggs/day vs. SUB | Serum LDL | ↑ in HC |
| Serum HDL | ↑ in both HL and HC | ||||||
aAbbreviations: CHD, coronary heart disease; CVD, cardiovascular disease; MI, myocardial infarction; LDL, low-density lipoprotein; HDL, high-density lipoprotein; SREBP, sterol regulatory element-binding protein; CETP, cholesteryl ester transfer protein; LCAT, lecithin-cholesterol acyltransferase; CRD, Carbohydrate-restricted diets; SUB, cholesterol-free, fat-free egg substitute; HC, hypercholesterolemia; HL, hyperlipidemia; b↑ increase, ↓ decrease, (-) no influence. cIntervention time contain a 3-weeks washout time within the intervention period; dhyperresponders: increase in total cholesterol of ≥0.06 mmol/L for each additional 100 mg of dietary cholesterol consumed.